Med24
overweight-obesity 12. 8. 2026 • 2 min read • Cureus

Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response Evidence

Heart failure with preserved ejection fraction (HFpEF) is increasingly understood as a heterogeneous syndrome in which cardiometabolic and functional phenotypes may influence treatment response beyond ejection fraction alone. This systematic review synthesized recent clinical and trial-derived evidence published from...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

This systematic review examined cardiometabolic phenotypes and therapeutic response in adults with heart failure with preserved ejection fraction (HFpEF) or closely related heart failure populations from June 2025 to May 2026. The search included PubMed/MEDLINE, Scopus, and Web of Science, utilizing terms related to HFpEF, diabetes, obesity, adiposity, frailty, exercise function, and treatment outcomes. Six studies met the inclusion criteria, encompassing randomized trials, pooled analyses, and crossover trial evidence. These studies investigated tirzepatide, semaglutide, dapagliflozin, and dapagliflozin plus spironolactone, assessing their effects across various phenotypes.

Key Clinical Findings

Included studies evaluated outcomes related to type 2 diabetes, body mass index (BMI), central adiposity, achieved weight loss, epicardial or paracardiac fat, exercise limitation, frailty, and renal-electrolyte profile. Contemporary cardiometabolic therapies demonstrated improvements in heart failure outcomes, patient-reported health status, exercise capacity, body weight, natriuretic peptides, adiposity measures, cardiac remodeling markers, and frailty burden.

Sponsored content

Diabetes did not uniformly attenuate heart failure benefit, despite less weight loss. Adiposity distribution, functional limitation, frailty, and local cardiac fat may represent clinically relevant domains for interpreting treatment response. Sodium-glucose cotransporter 2 inhibitor-based therapy showed potential cardiometabolic, renal, hemodynamic, and structural effects, requiring careful renal and potassium monitoring. Overall, the findings suggest a potential value of a phenotype-informed framework for evaluating treatment response in HFpEF. However, the evidence is primarily derived from secondary analyses, limiting its utility for phenotype-guided treatment selection. Prospective studies are needed to determine if integrating these factors can improve treatment selection beyond ejection fraction and BMI alone.

Original Scientific Source
Cureus
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study
overweight-obesity

Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

Summary Background Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods We analysed genome-wide data...

28. 10. 2026 Read article →
The interpretation of body-composition metrics in obesity
overweight-obesity

The interpretation of body-composition metrics in obesity

Modern obesity care is increasingly therapeutic, longitudinal, and outcome-oriented, yet clinical assessment often remains centered on total body weight and BMI. Although BMI remains useful for screening and population-level risk stratification, it cannot characterize the biological heterogeneity of obesity or the...

26. 10. 2026 Read article →
Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial
overweight-obesity

Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial

Background Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to 2 and adiposity-related complications have not been characterized....

14. 10. 2026 Read article →
Advertisement